549 related articles for article (PubMed ID: 15710957)
21. The effect of pegylated interferon-alpha on the treatment of lamivudine resistant chronic HBeAg positive hepatitis B virus infection.
Leemans WF; Flink HJ; Janssen HL; Niesters HG; Schalm SW; de Man RA
J Hepatol; 2006 Mar; 44(3):507-11. PubMed ID: 16457904
[TBL] [Abstract][Full Text] [Related]
22. A randomized controlled trial of pegylated interferon-alpha2a plus adefovir dipivoxil for hepatitis B e antigen-negative chronic hepatitis B.
Piccolo P; Lenci I; Demelia L; Bandiera F; Piras MR; Antonucci G; Nosotti L; Mari T; De Santis A; Ponti ML; Sorbello O; Iacomi F; Angelico M
Antivir Ther; 2009; 14(8):1165-74. PubMed ID: 20032546
[TBL] [Abstract][Full Text] [Related]
23. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial.
Schalm SW; Heathcote J; Cianciara J; Farrell G; Sherman M; Willems B; Dhillon A; Moorat A; Barber J; Gray DF
Gut; 2000 Apr; 46(4):562-8. PubMed ID: 10716688
[TBL] [Abstract][Full Text] [Related]
24. A pilot study of extended duration peginterferon alfa-2a for patients with hepatitis B e antigen-negative chronic hepatitis B.
Gish RG; Lau DT; Schmid P; Perrillo R
Am J Gastroenterol; 2007 Dec; 102(12):2718-23. PubMed ID: 17662102
[TBL] [Abstract][Full Text] [Related]
25. Sequential combination therapy of HBe antigen-negative/virus-DNA-positive chronic hepatitis B with famciclovir or lamivudine and interferon-alpha-2a.
Schiefke I; Klecker C; Maier M; Oesen U; Etzrodt G; Tannapfel A; Liebert UG; Berr F
Liver Int; 2004 Apr; 24(2):98-104. PubMed ID: 15078472
[TBL] [Abstract][Full Text] [Related]
26. Long-term follow-up of peginterferon and lamivudine combination treatment in HBeAg-positive chronic hepatitis B.
Chan HL; Hui AY; Wong VW; Chim AM; Wong ML; Sung JJ
Hepatology; 2005 Jun; 41(6):1357-64. PubMed ID: 15880608
[TBL] [Abstract][Full Text] [Related]
27. Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B.
Lampertico P; Viganò M; Di Costanzo GG; Sagnelli E; Fasano M; Di Marco V; Boninsegna S; Farci P; Fargion S; Giuberti T; Iannacone C; Regep L; Massetto B; Facchetti F; Colombo M;
Gut; 2013 Feb; 62(2):290-8. PubMed ID: 22859496
[TBL] [Abstract][Full Text] [Related]
28. Interferon-alpha plus lamivudine vs lamivudine reduces breakthroughs, but does not affect sustained response in HBeAg negative chronic hepatitis B.
Economou M; Manolakopoulos S; Trikalinos TA; Filis S; Bethanis S; Tzourmakliotis D; Avgerinos A; Raptis S; Tsianos EV
World J Gastroenterol; 2005 Oct; 11(37):5882-7. PubMed ID: 16270403
[TBL] [Abstract][Full Text] [Related]
29. Peg-interferon improves liver histology in patients with HBeAg-positive chronic hepatitis B: no additional benefit of combination with lamivudine.
van Zonneveld M; Zondervan PE; Cakaloglu Y; Simon C; Akarca US; So TM; Flink HJ; de Man RA; Schalm SW; Janssen HL;
Liver Int; 2006 May; 26(4):399-405. PubMed ID: 16629642
[TBL] [Abstract][Full Text] [Related]
30. Extended treatment with peginterferon α-2a in combination with lamivudine or adefovir for 96 weeks yields high rates of HBeAg and HBsAg seroconversion.
Cao ZH; Ma LN; Zhang HW; Liu YL; Chen XY
J Dig Dis; 2013 Aug; 14(8):446-50. PubMed ID: 23615131
[TBL] [Abstract][Full Text] [Related]
31. Combination alpha-interferon and lamivudine therapy for alpha-interferon-resistant chronic hepatitis B infection: results of a pilot study.
Mutimer D; Naoumov N; Honkoop P; Marinos G; Ahmed M; de Man R; McPhillips P; Johnson M; Williams R; Elias E; Schalm S
J Hepatol; 1998 Jun; 28(6):923-9. PubMed ID: 9672165
[TBL] [Abstract][Full Text] [Related]
32. Antiviral therapy in hepatitis B virus-infected children with immune-tolerant characteristics: A pilot open-label randomized study.
Zhu S; Zhang H; Dong Y; Wang L; Xu Z; Liu W; Gan Y; Tang H; Chen D; Wang F; Zhao P
J Hepatol; 2018 Jun; 68(6):1123-1128. PubMed ID: 29452204
[TBL] [Abstract][Full Text] [Related]
33. [Factors associated with response to lamivudine: retrospective study of 233 patients with chronic hepatitis B].
Zhou HJ; Li SG; Wen FY; Yang XY; Wu JL; Tan B; Fu J
Zhonghua Gan Zang Bing Za Zhi; 2009 Aug; 17(8):564-8. PubMed ID: 19719911
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of peginterferon alpha-2a (40KD) in HBeAg-positive chronic hepatitis B patients.
Caruntu FA; Streinu-Cercel A; Gheorghe LS; Grigorescu M; Sporea I; Stanciu C; Andronescu D; Voinea F; Diculescu M; Oproiu A; Voiosu R
J Gastrointestin Liver Dis; 2009 Dec; 18(4):425-31. PubMed ID: 20076814
[TBL] [Abstract][Full Text] [Related]
35. Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B.
Bonino F; Marcellin P; Lau GK; Hadziyannis S; Jin R; Piratvisuth T; Germanidis G; Yurdaydin C; Diago M; Gurel S; Lai MY; Brunetto MR; Farci P; Popescu M; McCloud P;
Gut; 2007 May; 56(5):699-705. PubMed ID: 17127704
[TBL] [Abstract][Full Text] [Related]
36. Sequential treatment with lamivudine and interferon monotherapies in patients with chronic hepatitis B not responding to interferon alone: results of a pilot study.
Serfaty L; Thabut D; Zoulim F; Andreani T; Chazouillères O; Carbonell N; Loria A; Poupon R
Hepatology; 2001 Sep; 34(3):573-7. PubMed ID: 11526544
[TBL] [Abstract][Full Text] [Related]
37. Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-α2b: relation to response and HBV genotype.
Sonneveld MJ; Rijckborst V; Cakaloglu Y; Simon K; Heathcote EJ; Tabak F; Mach T; Boucher CA; Hansen BE; Zeuzem S; Janssen HL
Antivir Ther; 2012; 17(1):9-17. PubMed ID: 22267464
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of thymosin α-1 plus peginterferon α-2a combination therapy compared with peginterferon α-2a monotherapy in HBeAg-positive chronic hepatitis B: a prospective, multicenter, randomized, open-label study.
Kim BH; Lee YJ; Kim W; Yoon JH; Jung EU; Park SJ; Kim YJ; Lee HS
Scand J Gastroenterol; 2012 Sep; 47(8-9):1048-55. PubMed ID: 22726105
[TBL] [Abstract][Full Text] [Related]
39. Treatment of chronic hepatitis B with the sequential administration of interferon and lamivudine.
Hasan F; al-Khaldi J; Asker H; Varghese R; Siddique I; al-Shammali M; al-Kalaoui M; al-Nakib B
Hepatogastroenterology; 2003; 50(54):2040-2. PubMed ID: 14696461
[TBL] [Abstract][Full Text] [Related]
40. Peginterferon-alpha-2a (40 kD): A review of its use in chronic hepatitis B.
Keating GM
Drugs; 2009; 69(18):2633-60. PubMed ID: 19943712
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]